In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|August 7, 2017
How is Janssen's New HIV-1 Vaccine Regimen Unique?
Author(s)Contagion Editorial Staff
Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
Advertisement
Hanneke Schuitemaker, PhD, Vice President and Head of Viral Vaccines Discovery and Translational Medicine at Janssen Vaccines, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
Interview Transcript (slightly modified for readability):
“The vaccine differs from other regimens in that we are using low-seroprevalent adenoviral vectors that seem to really have a unique type of immunoresponse that they elicit. The antibodies that are being elicited by these vectors, in combination with the protein that we have in our regimen, seem to have really unique functionalities that are not being elicited by other vaccines. Whether this will be the unique feature that will give protection, or a higher level of protection, remains to be seen. We seem to have pretty
Advertisement
Related to this article
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement
Trending on Contagion Live
1
Measles Update: September 25, 2026
2
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
3
US Company Recalls Thousands of Pounds of Uninspected Meat
4
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
5